Healthcare
Live Price
Offline$2.20
+0.00% today
Window Change
-13.73%
Window
May 29, 2026 β Jun 12, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 11 bars Β· May 29, 2026 β Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
3SBio Inc. (TRSBF) is a Healthcare stock with a market cap of $49.45B and listed on OTC. The stock last traded around $2.20 and down 13.7% across the available one-year price window (May 29, 2026 β Jun 12, 2026). Baseline metrics include revenue growth of +89.3%, EPS growth of +298.8%, a dividend yield of 1.1%. What stands out right now is revenue +89.3%, EPS +298.8%, free cash flow +307.8% with operating margin 59.6% and ROIC 26.1%. The dividend is present but secondary, with a yield around 1.1%. Valuation is more restrained than many high-expectation growth names at P/E 5.7 and price/sales 2.8. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines TRSBF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TRSBF
β
Normalized return
SPY
β
S&P 500
Excess Return
β
Relative to SPY
TRSBF Max Drawdown
-21.57%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Uses the longest available daily history for TRSBF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$5.6B
-12.4% YoY
FY Net Income
$835.8M
-49.4% YoY
Free Cash Flow
$363.1M
-16.1% YoY
Revenue Growth
+89.3%
EPS Growth
+298.8%
Gross Margin
92.4%
Net Margin
47.9%
Income statement
CNY
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 9.1B | 7.8B | 6.9B | 6.4B | 5.6B |
| Gross Profit | 7.8B | 6.6B | 5.7B | 5.3B | 4.5B |
| Operating Income | 2.7B | 2.5B | 2.1B | 1.8B | 1.5B |
| EBITDA | 3.3B | 2.5B | 2.8B | 2.3B | 1.7B |
| Net Income | 2.1B | 1.5B | 1.9B | 1.7B | 836M |
| EPS (Diluted) | β | β | β | β | β |
Balance sheet
CNY
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2.0B | 2.7B | 2.1B | 2.8B | 3.1B |
| Total Assets | 24.2B | 23.6B | 22.0B | 19.2B | 17.7B |
| Total Liabilities | 6.2B | 7.1B | 6.6B | 4.6B | 4.6B |
| Shareholder Equity | 15.4B | 14.0B | 13.0B | 12.2B | 10.7B |
| Total Debt | 3.6B | 4.8B | 4.5B | 2.6B | 2.9B |
| Net Debt | 1.5B | 2.1B | 2.3B | -174M | -176M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1.3B
-14.8% YoY
Capital Expenditures
981M
+14.3% YoY
Free Cash Flow
363M
-16.1% YoY
Key ratios
Gross Margin
92.4%
Operating Margin
59.6%
Net Margin
47.9%
ROE
38.4%
Debt / Equity
0.10x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.